0.099 USD
-0.06 (-36.94%)
0.101 USD
+0 (+2.02%)
ChartMill assigns a Buy % Consensus number of 78% to CRXT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.06. This target is 2990.91% above the current price.
CRXT was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CRXT.
In the previous month the buy percentage consensus was at a similar level.
CRXT was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-23 | Needham | Downgrade | Buy -> Hold |
| 2022-08-22 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-05-17 | Needham | Maintains | Buy |
| 2022-05-17 | Truist Securities | Maintains | Buy |
| 2021-10-13 | Truist Securities | Initiate | Buy |
| 2021-10-06 | Needham | Initiate | Buy |
| 2021-09-29 | Maxim Group | Initiate | Buy |
| 2021-09-20 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-09-20 | Oppenheimer | Initiate | Outperform |
CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ
Can you provide the average price target for CLARUS THERAPEUTICS HOLDINGS stock?
9 analysts have analysed CRXT and the average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099.
What is the consensus rating for CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?
The consensus rating for CLARUS THERAPEUTICS HOLDINGS (CRXT) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed CLARUS THERAPEUTICS HOLDINGS (CRXT)?
The number of analysts covering CLARUS THERAPEUTICS HOLDINGS (CRXT) is 9.